{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:09:26Z","timestamp":1789027766559,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universidade Do Vale Do Taquari"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer remains a significant public health challenge globally, with marked regional disparities in Brazil linked to demographic, socioeconomic, and healthcare access factors. This study analyzed trends in disability-adjusted life years (DALYs), incidence, mortality, and prevalence of prostate cancer across Brazilian macroregions (1990\u20132021) using data from the Global Burden of Disease (GBD) database. Joinpoint regression was employed to identify temporal trends and average annual percentage changes (AAPCs), stratified by age and region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from GBD 2021, encompassing national and regional estimates. Statistical analyses included age-standardized rates, AAPC calculations, and pairwise comparisons to assess parallelism in trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results revealed substantial regional disparities: Southern and Southeastern regions exhibited the highest DALYs, incidence, and prevalence, patterns that are consistent with better diagnostic infrastructure and aging populations. In contrast, Northern regions showed lower rates but the steepest AAPC increases (e.g., incidence:\u2009+\u20092.59% annually in age group 70\u201374), suggestive of improving yet insufficient healthcare access. Mortality declined in the South and Southeast (AAPC up to \u22120.70% in age group 70\u201374) due to therapeutic advances but rose in the Northeast (AAPC up to\u2009+\u20090.76% in age group 65\u201369). Prevalence surged nationwide, peaking in older age groups (e.g., 2,619.50 cases\/100,000 men in Southern 70\u201374 age group), indicating prolonged survival. Joinpoint analyses identified non-linear trends, with incidence stabilizing post-2010 following shifts in screening guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings underscore the need for region-specific policies to address inequities in cancer care, enhance early diagnosis, and optimize resource allocation. Strengthening healthcare infrastructure in underserved regions and targeted screening for younger high-risk populations are critical to mitigating Brazil\u2019s prostate cancer burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10552-026-02232-2","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T10:52:39Z","timestamp":1787136759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global burden of prostate cancer (1990\u20132021) from Brazil: trends in disability-adjusted life years, incidence, mortality, and prevalence"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8298-2109","authenticated-orcid":false,"given":"Gabriela","family":"Daiprai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1998-1494","authenticated-orcid":false,"given":"Bruna Cristina Jordon","family":"Togni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3830-0855","authenticated-orcid":false,"given":"Maria No\u00eamia Souza","family":"de Alc\u00e2ntara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5800-194X","authenticated-orcid":false,"given":"Joana","family":"Ecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5591-078X","authenticated-orcid":false,"given":"\u00c1gatha Kniphoff","family":"da Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7955-078X","authenticated-orcid":false,"given":"Fernanda","family":"Majolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6619-6622","authenticated-orcid":false,"given":"Guilherme Liberato","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2232_CR1","unstructured":"Instituto Nacional De C\u00e2ncer (INCA). Estimativa 2023: Incid\u00eancia de C\u00e2ncer no Brasil. 2023. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/inca-lanca-a-estimativa-2023-incidencia-de-cancer-no-brasil\/. Accessed 27 May 2025"},{"issue":"1","key":"2232_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5433\/ahi.2024.v13.n1.83","volume":"13","author":"IA da Silva","year":"2024","unstructured":"da Silva IA, Messias MCA, Weller M (2024) Fatores de Risco Associados ao Desenvolvimento do C\u00e2ncer de Pr\u00f3stata: uma Revis\u00e3o da Literatura Brasileira. Archives Health Invest 13(1):83\u201391. https:\/\/doi.org\/10.5433\/ahi.2024.v13.n1.83","journal-title":"Archives Health Invest"},{"issue":"18","key":"2232_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","volume":"364","author":"A Bill-Axelson","year":"2011","unstructured":"Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, H\u00e4ggman M, Andersson SO, Bratell S, Sp\u00e5ngberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, SPCG-4 Investigators (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa1011967","journal-title":"N Engl J Med"},{"key":"2232_CR4","unstructured":"SBU (SOCIEDADE BRASILEIRA DE UROLOGIA). Novembro Azul 2023\u2013\u2013Dados e recomenda\u00e7\u00f5es. Rio de Janeiro: SBU, 2023. Dispon\u00edvel em: https:\/\/portaldaurologia.org.br\/. Accessed 20 May 2025"},{"issue":"6","key":"2232_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1590\/S1677-5538.IBJU.2015.0690","volume":"42","author":"RR Tourinho-Barbosa","year":"2016","unstructured":"Tourinho-Barbosa RR, Pompeo AC, Glina S (2016) Prostate cancer in Brazil and Latin America: epidemiology and screening. Int Braz J Urol 42(6):1081\u20131090. https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2015.0690","journal-title":"Int Braz J Urol"},{"key":"2232_CR6","unstructured":"OBSERVAT\u00d3RIO DE ONCOLOGIA. Panorama da Radioterapia no Brasil entre 2018 e 2023. 2024. Dispon\u00edvel em: https:\/\/observatoriodeoncologia.com.br\/estudos\/tratamento-em-oncologia\/2024\/panorama-da-radioterapia-no-brasil-entre-2018-e-2023\/. Acesso em: 27 maio 2025"},{"issue":"2","key":"2232_CR7","first-page":"70","volume":"60","author":"AM Wolf","year":"2010","unstructured":"Wolf AM, Wender RC, Etzioni RB, Thompson IM, D\u2019Amico AV, Volk RJ et al (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60(2):70\u201398","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2232_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/MED.0b013e328360332a","volume":"20","author":"L Klotz","year":"2013","unstructured":"Klotz L (2013) Prostate cancer overdiagnosis and overtreatment. Curr Opin Endocrinol Diabetes Obes 20(3):204\u2013209. https:\/\/doi.org\/10.1097\/MED.0b013e328360332a","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"(6 Suppl)","key":"2232_CR9","doi-asserted-by":"publisher","first-page":"273S","DOI":"10.1016\/s0197-2456(00)00098-2","volume":"21","author":"PC Prorok","year":"2000","unstructured":"Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O\u2019Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK (2000) Prostate, lung, colorectal and ovarian cancer screening trial project team. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21((6 Suppl)):273S-309S. https:\/\/doi.org\/10.1016\/s0197-2456(00)00098-2","journal-title":"Control Clin Trials"},{"issue":"13","key":"2232_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, M\u00e4\u00e4tt\u00e4nen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320\u20131328. https:\/\/doi.org\/10.1056\/NEJMoa0810084","journal-title":"N Engl J Med"},{"issue":"18","key":"2232_CR11","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"DC Grossman","year":"2018","unstructured":"US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Siu AL, Tseng CW (2018) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319(18):1901\u20131913. https:\/\/doi.org\/10.1001\/jama.2018.3710","journal-title":"JAMA"},{"key":"2232_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.11606\/s1518-8787.2020054001948","volume":"54","author":"CTM Luizaga","year":"2020","unstructured":"Luizaga CTM, Ribeiro KB, Fonseca LAM, Eluf NJ (2020) Trends in prostate cancer mortality in the state of S\u00e3o Paulo, 2000 to 2015. Rev Saude Publica 54:87. https:\/\/doi.org\/10.11606\/s1518-8787.2020054001948","journal-title":"Rev Saude Publica"},{"key":"2232_CR13","unstructured":"Institute for Health Metrics and Evaluation\u2013\u2013IHME. Global burden of disease. Seattle,WA: IHME, University of Washington; 2025. Dispon\u00edvel em: https:\/\/vizhub.healthdata.org\/gbd-compare\/. Accessed 18 Feb 2025"},{"issue":"10258","key":"2232_CR14","first-page":"1204","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2019","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2019) Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222","journal-title":"Lancet"},{"key":"2232_CR15","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020b. 396(10258):1223\u201349"},{"issue":"4","key":"2232_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"Global Burden of Disease Cancer Collaboration","year":"2017","unstructured":"Global Burden of Disease Cancer Collaboration (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3(4):524\u2013548. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5688","journal-title":"JAMA Oncol"},{"issue":"10440","key":"2232_CR17","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators (2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2100\u20132132. https:\/\/doi.org\/10.1016\/S0140-6736(24)00367-2","journal-title":"Lancet"},{"key":"2232_CR18","unstructured":"World Health Organization - WHO. Disability-adjusted life years (DALYs), 2022. Dispon\u00edvel em: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/158. Accessed 18 Feb 2025"},{"key":"2232_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2020","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, Bray F (2020) Cancer statistics for the year 2020: an overview. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33588","journal-title":"Int J Cancer"},{"key":"2232_CR20","unstructured":"Joinpoint Regression Program, Version 5.4.0.0\u2013\u2013April 2025; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute."},{"issue":"3","key":"2232_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z.Erratum.In:StatMed2001;20(4):655","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19(3):335\u2013351. https:\/\/doi.org\/10.1002\/(sici)1097-0258(20000215)19:3%3c335::aid-sim336%3e3.0.co;2-z.Erratum.In:StatMed2001;20(4):655","journal-title":"Stat Med"},{"issue":"16","key":"2232_CR22","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1002\/sim.9407","volume":"41","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Chen HS, Byrne J, Wheeler B, Feuer EJ (2022) Twenty years since Joinpoint 1.0: two major enhancements, their justification, and impact. Stat Med 41(16):3102\u20133130. https:\/\/doi.org\/10.1002\/sim.9407","journal-title":"Stat Med"},{"issue":"4","key":"2232_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/JS9.0000000000001054","volume":"110","author":"Z Li","year":"2024","unstructured":"Li Z, Zhang X, Sun C, Li Z, Fei H, Zhao D (2024) Global, regional, and national burdens of early onset pancreatic cancer in adolescents and adults aged 15-49 years from 1990 to 2019 based on the Global Burden of Disease Study 2019: a cross-sectional study. Int J Surg 110(4):1929\u20131940. https:\/\/doi.org\/10.1097\/JS9.0000000000001054","journal-title":"Int J Surg"},{"key":"2232_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1612702","author":"M Du","year":"2019","unstructured":"Du M, Chen W, Liu K, Wang L, Hu Y, Mao Y, Sun X, Luo Y, Shi J, Shao K et al (2019) The Global Burden of Leukemia and its attributable factors in 204 countries and territories: findings from the Global Burden of Disease 2019 Study and projections to 2030. J Oncol. https:\/\/doi.org\/10.1155\/2022\/1612702","journal-title":"J Oncol"},{"issue":"8","key":"2232_CR25","doi-asserted-by":"publisher","DOI":"10.25248\/reas.e16020.2024","volume":"24","author":"MAA Santos-Filho","year":"2024","unstructured":"Santos-Filho MAA, Sab Y, Barros JMT, Porto LA (2024) Tend\u00eancias na mortalidade por c\u00e2ncer de pr\u00f3stata no Brasil ao longo de duas d\u00e9cadas 2000\u20132020. Rev Eletron Acervo Saude 24(8):e16020. https:\/\/doi.org\/10.25248\/reas.e16020.2024","journal-title":"Rev Eletron Acervo Saude"},{"issue":"9","key":"2232_CR26","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s11255-023-03653-7","volume":"55","author":"J Guzman-Esquivel","year":"2023","unstructured":"Guzman-Esquivel J, Murillo-Zamora E, Ortiz-Mesina M, Galvan-Salazar HR, De-Leon-Zaragoza L, Casarez-Price JC, Delgado-Enciso J, Delgado-Enciso I (2023) Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019. Int Urol Nephrol 55(9):2155\u20132160. https:\/\/doi.org\/10.1007\/s11255-023-03653-7","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"2232_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"key":"2232_CR28","doi-asserted-by":"publisher","unstructured":"American Cancer Society. Cancer Screening Guidelines for the Early Detection of Cancer in Asymptomatic People. CA: A Cancer Journal for Clinicians 2010; 60(2):70\u201398. https:\/\/doi.org\/10.3322\/caac.20107.","DOI":"10.3322\/caac.20107"},{"key":"2232_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3710","author":"USPSTF","year":"2018","unstructured":"USPSTF (2018) Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. https:\/\/doi.org\/10.1001\/jama.2018.3710","journal-title":"JAMA"},{"issue":"6","key":"2232_CR30","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/ijc.29894","volume":"138","author":"CK Zhou","year":"2016","unstructured":"Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook MB, Devesa SS (2016) Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer 138(6):1388\u20131400. https:\/\/doi.org\/10.1002\/ijc.29894","journal-title":"Int J Cancer"},{"issue":"6","key":"2232_CR31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djab122","volume":"114","author":"KR Yabroff","year":"2022","unstructured":"Yabroff KR, Wu XC, Negoita S, Stevens J, Coyle L, Zhao J, Mumphrey BJ, Jemal A, Ward KC (2022) Association of the COVID-19 pandemic with patterns of statewide cancer services. J Natl Cancer Inst 114(6):907\u2013909. https:\/\/doi.org\/10.1093\/jnci\/djab122","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2232_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030503","volume":"16","author":"JH Pyun","year":"2024","unstructured":"Pyun JH, Ko YH, Kim SW, Son N-H (2024) The short- and long-term anticipation of prostate cancer incidence in Korea: based on social aging trends and prostate-specific antigen testing rate during the last decade. Cancers 16(3):503. https:\/\/doi.org\/10.3390\/cancers16030503","journal-title":"Cancers"},{"issue":"2","key":"2232_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1055-9965","volume":"25","author":"RM Hoffman","year":"2016","unstructured":"Hoffman RM, Meisner AL, Arap W, Barry M, Shah SK, Zeliadt SB, Wiggins CL (2016) Trends in United States Prostate Cancer Incidence Rates by Age and Stage, 1995\u20132012. Cancer Epidemiol Biomarkers Prev 25(2):259\u2013263. https:\/\/doi.org\/10.1158\/1055-9965","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2232_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.puhe.2019.04.016","volume":"172","author":"X Liu","year":"2019","unstructured":"Liu X, Yu C, Bi Y, Zhang ZJ (2019) Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China. Public Health 172:70\u201380. https:\/\/doi.org\/10.1016\/j.puhe.2019.04.016","journal-title":"Public Health"},{"issue":"1","key":"2232_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","volume":"71","author":"S Carlsson","year":"2017","unstructured":"Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H (2017) Screening for prostate cancer starting at age 50-54 years. A population-based cohort study. Eur Urol 71(1):46\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2016.03.026","journal-title":"Eur Urol"},{"issue":"3","key":"2232_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249009","volume":"16","author":"CA Lima","year":"2021","unstructured":"Lima CA, da Silva BEB, Hora EC, Lima MS, Brito EAC, Santos MO, da Silva AM, Nunes MAP, Brito HLF, Lima MMM (2021) Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state. PLoS ONE 16(3):e0249009. https:\/\/doi.org\/10.1371\/journal.pone.0249009","journal-title":"PLoS ONE"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-026-02232-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-026-02232-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:48:56Z","timestamp":1789026536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-026-02232-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2232"],"URL":"https:\/\/doi.org\/10.1007\/s10552-026-02232-2","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no declarations of interest and non-financial interests to disclose.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"147"}}